Non-randomized, Non-blinded, Non-placebo-controlled Study to Investigate the Influence of Repeated Daily Administration of 600 mg Rifampicin Given Once Daily Over 11 Days on the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of 4 mg Vilaprisan in Healthy Postmenopausal Women.
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Midazolam (Primary) ; Rifampicin (Primary) ; Vilaprisan (Primary)
- Indications Endometriosis; Uterine leiomyoma
- Focus Pharmacokinetics
- Sponsors Bayer
- 01 Jun 2017 Status changed from active, no longer recruiting to completed.
- 08 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Apr 2017.
- 10 Feb 2017 Status changed from recruiting to active, no longer recruiting.